Guildford, UK – 06 February 2019: HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces today that it will present a poster entitled “Targeting of HOX-PBX binding in glioblastoma multiforme as a novel therapeutic treatment” at the American Association for Cancer Research Annual Meeting 2019 in Atlanta, Georgia, USA.
Professor Richard Morgan co-founder of HOX Therapeutics will present on Wednesday, 3 April 2019, from 8am EST to 12pm EST in Exhibit Hall B at the Georgia World Congress Center. The poster presentation will be part of the session “Mechanisms and Consequences of Transcriptional Deregulation”.
The AACR Annual Meeting programme covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of cancer experts in research and medicine from institutions all over the world.
The HOX Therapeutics technology has potential applicability across many cancer types, offering a novel modality to develop therapeutics. The Company is initially focused on developing innovative therapies for brain cancer and prostate cancer, huge areas of major unmet medical need. It aims to take its lead asset HTL-001 to treat brain cancer into clinical development in 2019.
For more information, please contact:
HOX Therapeutics Limited
Karl Keegan, CEO
Tel: +44 778 632 5650
Optimum Strategic Communications
Mary Clark, Hollie Vile, Manel Mateus
Tel: +44 203 950 9144
HOX Therapeutics is developing innovative, first-in-class and highly targeted cancer therapies. Its scientific approach is based on the over expression and unique role of developmental HOX genes in tumour biology and pathogenesis. The HOX genes offer a novel therapeutic target in cancer biology with potential applicability across many cancer types. Largely silenced just after birth, aberrant HOX gene expression has been shown to have pro-oncogenic effects. There is increasing recognition that re-activation of HOX genes is involved in the pathogenesis of common cancers. HOX proteins bind to DNA in combination with a co-factor, Pre-B-cell Leukaemia Homeobox (PBX). The Company was founded by world leading experts in HOX gene family biology and clinical oncology, Professor Hardev Pandha, Head of Oncology, University of Surrey and Professor Richard Morgan, Institute of Cancer Therapeutics, Bradford. The Company is initially focused on novel treatments for brain and prostate cancer. For more information: www.hoxtherapeutics.com